The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction
Open accessAbstract
The effective use of targeted therapy is highly dependent on the identification of responder patient populations. Loss of FBW7, which encodes a tumour-suppressor protein, is frequently found in various types of human cancer, including breast cancer, colon cancer and T-cell acute lymphoblastic leukaemia (T-ALL). In line with these genomic data, engineered deletion of Fbw7 in mouse T cells results in T-ALL, validating FBW7 as a T-ALL tumour suppressor. Determining the precise molecular mechanisms by which FBW7 exerts antitumour activity is an area of intensive investigation. These mechanisms are thought to relate in part to FBW7-mediated destruction of key proteins relevant to cancer, including Jun, Myc, cyclin E and notch 1 (ref. 9), all of which have oncoprotein activity and are overexpressed in various human cancers, including leukaemia. In addition to accelerating cell growth, overexpression of Jun, Myc or notch 1 can also induce programmed cell death. Thus, considerable uncertainty surrounds how FBW7-deficient cells evade cell death in the setting of upregulated Jun, Myc and/or notch 1. Here we show that the E3 ubiquitin ligase SCFFBW7 (a SKP1–cullin-1–F-box complex that contains FBW7 as the F-box protein) governs cellular apoptosis by targeting MCL1, a pro-survival BCL2 family member, for ubiquitylation and destruction in a manner that depends on phosphorylation by glycogen synthase kinase 3. Human T-ALL cell lines showed a close relationship between FBW7 loss and MCL1 overexpression. Correspondingly, T-ALL cell lines with defective FBW7 are particularly sensitive to the multi-kinase inhibitor sorafenib but resistant to the BCL2 antagonist ABT-737. On the genetic level, FBW7 reconstitution or MCL1 depletion restores sensitivity to ABT-737, establishing MCL1 as a therapeutically relevant bypass survival mechanism that enables FBW7-deficient cells to evade apoptosis. Therefore, our work provides insight into the molecular mechanism of direct tumour suppression by FBW7 and has implications for the targeted treatment of patients with FBW7-deficient T-ALL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AP-1 as a regulator of cell life and death
Shaulian, E., & Karin, M. (2002) · Nature Cell Biology · doi:10.1038/ncb0502-e131 · Cited by 2,961
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,240
Welcker, M., & Clurman, B. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2290 · Cited by 1,084
Welcker, M., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N., & Clurman, B. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402770101 · Cited by 941
Maurer, U., Charvet, C., Wagman, A. S., Dejardin, E., & Green, D. R. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.009 · Cited by 881
Zhong, Q., Gao, W., Du, F., & Wang, X. (2005) · Cell · doi:10.1016/j.cell.2005.06.009 · Cited by 842
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1
Opferman, J. T., Letai, A., Beard, C., Sorcinelli, M. D., Ong, C. C., & Korsmeyer, S. J. (2003) · Nature · doi:10.1038/nature02067 · Cited by 801
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 794
Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCF Fbw7 Ubiquitin Ligase
Koepp, D. M., Schaefer, L. K., Ye, X., Keyomarsi, K., Chu, C., Harper, J. W., & Elledge, S. J. (2001) · Science · doi:10.1126/science.1065203 · Cited by 762
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., Maecker, H., O’Rourke, K., Bazan, F., Eastham-Anderson, J., et al. (2010) · Nature · doi:10.1038/nature08646 · Cited by 628
Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation
Nijhawan, D., Fang, M., Traer, E., Zhong, Q., Gao, W., Du, F., & Wang, X. (2003) · Genes & Development · doi:10.1101/gad.1093903 · Cited by 591
ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor
Chen, D., Kon, N., Li, M., Zhang, W., Qin, J., & Gu, W. (2005) · Cell · doi:10.1016/j.cell.2005.03.037 · Cited by 544
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia
Thompson, B. J., Buonamici, S., Sulis, M. L., Palomero, T., Vilimas, T., Basso, G., Ferrando, A., & Aifantis, I. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070872 · Cited by 480
The ubiquitin-specific protease USP28 is required for MYC stability
Popov, N., Wanzel, M., Madiredjo, M., Zhang, D., Beijersbergen, R., Bernards, R., Moll, R., Elledge, S. J., & Eilers, M. (2007) · Nature Cell Biology · doi:10.1038/ncb1601 · Cited by 474
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441
Self-citationWei, W., Jin, J., Schlisio, S., Harper, J. W., & Kaelin, W. G. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.005 · Cited by 403
Self-citationDing, Q., He, X., Hsu, J.-M., Xia, W., Chen, C.-T., Li, L.-Y., Lee, D.-F., Liu, J.-C., Zhong, Q., Wang, X., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00620-06 · Cited by 393
Gupta-Rossi, N., Le Bail, O., Gonen, H., Brou, C., Logeat, F., Six, E., Ciechanover, A., & Israël, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101343200 · Cited by 379
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers
Maser, R. S., Choudhury, B., Campbell, P. J., Feng, B., Wong, K.-K., Protopopov, A., O’Neil, J., Gutierrez, A., Ivanova, E., Perna, I., et al. (2007) · Nature · doi:10.1038/nature05886 · Cited by 377
Self-citationMcl-1 is a potential therapeutic target in multiple types of cancer
Akgul, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8637-6 · Cited by 329
Yu, C., Bruzek, L. M., Meng, X. W., Gores, G. J., Carter, C. A., Kaufmann, S. H., & Adjei, A. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208841 · Cited by 277
Gao, D., Inuzuka, H., Tseng, A., Chin, R. Y., Toker, A., & Wei, W. (2009) · Nature Cell Biology · doi:10.1038/ncb1847 · Cited by 267
Self-citationKonopleva, M., Watt, J., Contractor, R., Tsao, T., Harris, D., Estrov, Z., Bornmann, W., Kantarjian, H., Viallet, J., Samudio, I., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1919 · Cited by 265
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2615 · Cited by 185
Matsuoka, S., Oike, Y., Onoyama, I., Iwama, A., Arai, F., Takubo, K., Mashimo, Y., Oguro, H., Nitta, E., Ito, K., et al. (2008) · Genes & Development · doi:10.1101/gad.1621808 · Cited by 185
Self-citationOnoyama, I., Tsunematsu, R., Matsumoto, A., Kimura, T., de Alborán, I. M., Nakayama, K., & Nakayama, K. I. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062299 · Cited by 177
Self-citationInvolvement of the SCF Complex in the Control of Cdh1 Degradation in S-phase
Benmaamar, R., & Pagano, M. (2005) · Cell Cycle · doi:10.4161/cc.4.9.2048 · Cited by 64
GSK-3β Inhibition Enhances Sorafenib-induced Apoptosis in Melanoma Cell Lines
Panka, D. J., Cho, D. C., Atkins, M. B., & Mier, J. W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705343200 · Cited by 56
Sánchez, I., & Yuan, J. (2001) · Neuron · doi:10.1016/s0896-6273(01)00232-x · Cited by 26
Cited by
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Necroptosis, pyroptosis and apoptosis: an intricate game of cell death
Bertheloot, D., Latz, E., & Franklin, B. S. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00630-3 · Cited by 2,166
Mechanisms and function of substrate recruitment by F-box proteins
Skaar, J. R., Pagan, J. K., & Pagano, M. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3582 · Cited by 689
Metadata
- Authors
- Inuzuka, H., Shaik, S., Onoyama, I., Gao, D., Tseng, A., Maser, R. S., Zhai, B., Wan, L., Gutierrez, A., Lau, A. W., Xiao, Y., Christie, A. L., Aster, J., Settleman, J., Gygi, S. P., Kung, A. L., Look, T., Nakayama, K. I., DePinho, R. A., & Wei, W.
- Venue
- Nature
- Published
- 2011-03
- Volume
- 471
- Issue
- 7336
- Pages
- 104-109
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1987821813
- Cited by
- 632
- References
- 30
- FWCI
- 22.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.